ADDvise streamlines organization through new business area structure

28-10-2024   Regulatory press release

To enhance focus and efficiency, ADDvise is restructuring its two existing business areas, Lab and Healthcare, into separate operational units, each led by a dedicated director. This new structure is designed to optimize the organization, establish a clearer strategic focus, and strengthen the foundation for both organic growth and acquisitions. Additionally, the structure facilitates valuable knowledge-sharing across the group.

The Healthcare business area manufactures and supplies a diverse range of advanced medical technology, high-quality consumables, and pharmaceuticals. By combining innovative, proprietary products with established brands essential equipment is offered to both private and public healthcare providers. Fredrik Mella will take on the role of Head of Healthcare.

The Lab business area delivers comprehensive solutions for modern research environments, including laboratory furniture, safety ventilation, climate and clean rooms, and laboratory equipment. The products support global research and development, with a focus on the pharmaceutical industry and life sciences. Johan Seltborg will take on the role of Head of Lab.

“With this restructuring, we are strengthening our decentralized business model, focusing on the individual company. By reducing costs and improving efficiency, we enhance our ability to achieve both organic growth and growth through acquisitions. I am confident that this change will bring greater clarity, long-term value, and strengthen our capacity to achieve our growth strategy," says Staffan Torstensson, CEO of ADDvise.

Following this restructuring, ADDvise's group executive team will include Staffan Torstensson as CEO, Fredrik Mella as Head of Healthcare, Johan Seltborg as Head of Lab, Johan Irwe as interim CFO, and Hanna Myhrman as General Counsel and Head of M&A. Through cost and efficiency measures, annual costs for central functions are expected to decrease by SEK 18 million.

For further information, please contact:
Staffan Torstensson, CEO
+46 70 433 20 19
staffan.torstensson@addvisegroup.se

About ADDvise Group
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.

Latest press releases

Interim report 2025, January 1–June 30

Regulatory

In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses…

Invitation to presentation of interim report April 1 – June 30, 2025

Non-regulatory

ADDvise Group publishes its interim report April 1 – June 30, 2025 on Thursday, July 17, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and CFO, Johan Irwe, will present the report. Webcast If you wish to…

ADDvise announces that the conditions for early redemption of outstanding secured bonds have been fulfilled

Regulatory

ADDvise Group AB (publ) (“ADDvise” or the “Company”) announced on 14 May 2025 that ADDvise intends to redeem the Company’s outstanding senior secured bonds with ISIN SE0020180271 and ISIN NO0013180786 (the “Early Redemption”). The Early Redemption was conditional upon the entering into of the new secured facilities agreement of the equivalence of SEK 450 million…